An innovation award for LEVUCELL SB

LEVUCELL SB receives a European innovation award Innov’SPACE for its food safety application in broiler

Lallemand Animal Nutrition is pleased to announce that its probiotic yeast LEVUCELL SB (Saccharomyces cerevisiae boulardii CNCM I-1079), recently authorized in the European Union as a zootechnical additive for chickens and minor avian species for fattening (4d1703), received an innovation award from the organizers of French leading livestock exhibition SPACE: the Innov’Space, with the highest rating, two stars.

Matthieu Baulez, Global Category Manager – Monogastric Feed Additives, commented: “We are thrilled by this recognition as we truly believe LEVUCELL SB for broiler chickens is a real added value and a totally new approach for the whole poultry production chain, to mitigate salmonella carriage risks, from farm to fork. This is the first time that a feed additive is authorized in the European Union (EU) with a specific food safety function. This means the authorities have acknowledged the benefits of a probiotic feed additive beyond zootechnical performance, on end-product quality, a benefit for the whole food chain up to consumer”.

LEVUCELL SB is the probiotic yeast Saccharomyces cerevisiae boulardii CNCM I-1079, authorized in the European Union as a zootechnical additive for chickens and minor avian species for fattening (4d1703). LEVUCELL SB helps balance the gut microbiota and strengthens the animal’s natural defenses. Its effects in favor of better intestinal conditions in vivo show benefits for the reduction of carcass contamination by Salmonella spp. It is the first and only probiotic authorized to date in the European Union with a specific feature aimed at improving food safety. S. c. boulardii is widely documented and has been used for several decades in human medicine for the prevention and treatment of digestive disorders such as those associated with the use of antibiotics or infections related to Clostridium difficile.

©2018. Not all products are available in all markets nor are associated claims allowed in all regions.